dabrafenib plus trametinib demonstrates benefit in braf-mutant melanoma
Published 4 years ago • 493 plays • Length 0:53Download video MP4
Download video MP3
Similar videos
-
1:52
dr. long on dabrafenib/trametinib in braf v600e-mutant melanoma
-
6:28
dabrafenib and trametinib in braf-mutated nsclc
-
2:33
dr. sullivan discusses role of dabrafenib plus trametinib in melanoma
-
0:30
dr. postow on fda approval of adjuvant dabrafenib plus trametinib in braf-mutant melanoma
-
2:11
dr. georgina long on dabrafenib and trametinib in braf-mutated melanoma
-
0:59
the success of the dabrafenib and trametinib combination in braf-mutated melanoma
-
2:46
long-term outcomes with dabrafenib plus trametinib in braf v600-mutant melanoma
-
3:18
dabrafenib plus trametinib for the treatment of mnsclc
-
3:06
combi-d: phase 3 trial of dabrafenib plus trametinib in braf v600e/k-mutated melanoma
-
2:16
dr. rodabe n. amaria on dabrafenib plus trametinib in melanoma
-
6:16
dabrafenib plus trametinib for stage iii mutant melanoma
-
1:04
dr. wilson on long-term data with dabrafenib plus trametinib in melanoma
-
2:31
neoadjuvant therapy with trametinib and dabrafenib in high risk resectable braf-mutant melanoma
-
1:49
combi-ad: dabrafenib plus trametinib in advanced melanoma
-
0:54
activity of dabrafenib/trametinib combo in patients with melanoma brain metastases
-
2:12
phase iii combi-d study of dabrafenib and trametinib in patients with melanoma
-
2:19
dr. robert on 5-year analysis of dabrafenib/trametinib in braf v600-mutant melanoma
-
1:24
adverse events with dabrafenib/trametinib combination in melanoma
-
3:05
dabrafenib and trametinib: a promising combination for the treatment of melanoma